Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06403501

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Huashan Hospital, Fudan University

Shanghai, China

Location status: Recruiting

Location contact

Shuyang Zhao

CONTACT

[email protected]

13123927303

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with facial acne vulgaris (which includes the nose) from moderate to severe, has an Investigator's Global Assessment (IGA) score of 3 or 4; with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones);
  • Male or female, 12 years of age or older;
  • Subjects aged 18 years or older are required to provide informed consent and sign the written informed consent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of consent signing.

Exclusion criteria

  • Subject has greater than two (2) facial nodules;
  • Subject has any skin pathology or condition that could interfere with the investigator's clinical evaluation of the investigational drug;
  • Subject has used topical and systemic anti-acne medications or therapies;
  • Subject has received hormonal therapy for acne treatment;
  • Subject has used a skincare product with acne removal effect;
  • Subject has other serious underlying diseases such as mental illness or malignant tumors;
  • Subject has any of the clinically significant laboratory test indicators at screening;
  • Subject has known hypersensitivity or previous allergic reaction to multiple drugs, or any of the active or inactive components of the test articles;
  • Subject engaged in drug abuse or excessive alcohol intake;
  • Subject has uncontrolled hypertension; Subject has poorly controlled diabetes;
  • Subject is pregnant, lactating, or is planning to become pregnant during the study (both male and female); subject has positive pregnancy test result; subject is unable to practice highly effective contraception methods during the trial and within 3 months after the end of the trial;
  • Subject is currently enrolled or was enrolled in other clinical trials within 3 months prior to the initiation of treatment;
  • Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this clinical trial.

Treatment and study plan

Clascoterone

Drug

Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Other names: Winlevi (brand name)

Vehicle cream

Drug

Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.

Primary outcomes

  1. Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

    Time frame: Week 12

    Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

  2. Change From Baseline in Non-inflammatory Lesion (NIL) Counts

    Time frame: Week 12

    Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

  3. Change From Baseline in Inflammatory Lesion (IL) Counts

    Time frame: Week 12

    Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

Secondary outcomes

  1. Change From Baseline in Total Lesion Counts

    Time frame: Week 12

    Absolute change from Baseline in total lesions counts in each treatment group at Week 12.

  2. Percent Change From Baseline in Total Lesion Counts

    Time frame: Week 12

    Percent change from Baseline in total lesions counts in each treatment group at Week 12.

  3. Percent Change From Baseline in Inflammatory Lesion Counts

    Time frame: Week 12

    Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.

  4. Percent Change From Baseline in Non-inflammatory Lesion Counts

    Time frame: Week 12

    Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.

Sponsors and collaborators

Lead sponsor

Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
May 8, 2024
Registry last updated
Jul 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.